Sheridan, Wyoming, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [https://kylopeptides.com/] today published The State of Research Peptides 2026, a data-driven industry report examining a fast-growing market in which, the report finds, a research peptide can carry a 99% purity label and still contain far less actual peptide than a buyer assumes, while the certificate meant to prove quality is easy to fabricate and rarely verified.
The report synthesizes market data, the 2026 United States regulatory landscape, independent and peer-reviewed testing, and supply-chain figures into a single conclusion: in a market with no mandatory quality standard, the number on a label means little without the evidence behind it.
Key Findings From the Report:
- A purity percentage does not tell a researcher how much peptide they are getting: Because standard purity testing does not detect counterions, water, or fillers, a vial can measure 99% pure by HPLC and still be only 70% to 85% actual peptide by weight, a distinction the report notes is widely misunderstood outside analytical chemistry.
- Independent and peer-reviewed testing keeps finding the same problem: One independent testing operation reported in 2026 that close to 30% of the peptide vials it analyzed were mislabeled, incorrectly quantified, or contaminated. A peer-reviewed analysis of products from five manufacturers found that two-thirds fell below research-grade purity and that one product was an entirely different peptide than its documentation claimed.
- The certificate itself is often unreliable: Because research-use-only products carry no mandatory testing standard, there is no body auditing certificates of analysis and no penalty for fabricating one. The report argues that a certificate is only trustworthy when it is tied to a specific lot number, names the testing laboratory, and is published openly.
- The market is expanding faster than its standards: Credible research firms value the peptide market anywhere from roughly $47 billion to $141 billion for 2025, a threefold spread. Meanwhile, United States imports of hormone and peptide compounds from China roughly doubled in a year, to about $328 million across the first three quarters of 2025.
The report arrives during the most active regulatory year on record for peptides. In July 2026, a federal advisory committee recommended six of seven peptides for a compounding pathway, even as regulators tightened enforcement against sellers marketing unapproved compounds for human use. The report is framed strictly around laboratory research materials and takes no position on human use.
“In a market this large, the genuine answer to 'what's in this vial?' is too often 'nobody checked,” said Dr. Rupert Mills, Process Chemist at Kylo Peptides. “A purity figure is a real number, but on its own it's incomplete. It tells you how clean the peptide is, not how much of it you actually have, or whether it's even the right molecule. The only thing that closes that gap is full characterization from independent, accredited labs, published where anyone can read it. That's the standard the field is moving toward, and it can't come soon enough.”
Stricter Quality Standards Are the Need of the Hour
The report also details why Kylo publishes both purity and net peptide content on every certificate. In one Kylo BPC-157 lot, for example, a certificate reports 99.62% purity alongside 12.14 mg of net peptide content on a product labeled at 10 mg, answering both questions a researcher has: whether the material is the right molecule at high quality, and whether the stated amount is genuinely present. Every Kylo lot is tested across independent laboratories, with certificates published in a public library that buyers can check against the lot number on the vial.
The State of Research Peptides 2026 is available at kylopeptides.com.
About Kylo Peptides
Kylo Peptides (Kylo Labs LLC) is a United States supplier of research-use-only peptides for in-vitro laboratory research by qualified professionals. Peptides are synthesized and lyophilized in the USA, and every lot is verified through independent, ISO/IEC 17025-accredited testing with a lot-matched certificate of analysis published in a public COA library. Kylo's focus is research integrity and quality transparency: verification a researcher can check, rather than a claim they must take on trust.
This release concerns research-use-only laboratory materials. It does not describe, recommend, or encourage the use of any peptide or other compound in humans or animals. Products discussed have not been evaluated by the U.S. Food and Drug Administration for the uses discussed and are not intended to diagnose, treat, cure, or prevent any disease. Statements attributed to independent researchers and studies reflect their original published context.
Kylo Peptides (Kylo Labs LLC) 30 N Gould St, Ste R, Sheridan, WY 82801 support@kylopeptides.com +1 350 252 3314 kylopeptides.com
